David B Agus

Summary

Affiliation: Cedars-Sinai Medical Center
Country: USA

Publications

  1. ncbi request reprint Ductal adenocarcinoma of the prostate
    Ronald L Shazer
    Louis Warschaw Prostate Cancer Center, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Clin Adv Hematol Oncol 2:393-5; discussion 396. 2004
  2. ncbi request reprint Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy
    David B Agus
    Cedars Sinai Prostate Cancer Center, Los Angeles, CA 90048, USA
    J Clin Oncol 25:675-81. 2007
  3. ncbi request reprint Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer
    David B Agus
    Cedars Sinai Prostate Cancer Center and Medical Center, Los Angeles, CA 90048, USA
    J Clin Oncol 23:2534-43. 2005
  4. ncbi request reprint Update on HER-kinase-directed therapy in prostate cancer
    Mitchell E Gross
    Louis Warschaw Prostate Cancer Center, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Clin Adv Hematol Oncol 2:53-6, 64. 2004
  5. pmc HER kinase axis receptor dimer partner switching occurs in response to EGFR tyrosine kinase inhibition despite failure to block cellular proliferation
    Anjali Jain
    Sumner M Redstone Prostate Cancer Research Program, Cedars Sinai Medical Center, Los Angeles, California, USA
    Cancer Res 70:1989-99. 2010
  6. doi request reprint Beta-2-microglobulin expression correlates with high-grade prostate cancer and specific defects in androgen signaling
    Sheldon R Mink
    Louis Warschaw Prostate Cancer Center, Sumner M Redstone Prostate Cancer Research Program, Cedars Sinai Medical Center, Los Angeles, California, USA
    Prostate 70:1201-10. 2010
  7. pmc Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes
    Shannon M Mumenthaler
    Sumner M Redstone Prostate Cancer Research Program, Cedars Sinai Medical Center, Los Angeles, CA, USA
    Mol Cancer Ther 8:2882-93. 2009
  8. ncbi request reprint 2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth
    Noriyuki Takai
    Division of Hematology Oncology, Cedars Sinai Medical Center UCLA School of Medicine, Los Angeles, CA 90048, USA
    Cancer 104:2701-8. 2005
  9. doi request reprint Quantitative proteomic profiling identifies protein correlates to EGFR kinase inhibition
    Kian Kani
    University of Southern California, Los Angeles, CA 90033, USA
    Mol Cancer Ther 11:1071-81. 2012
  10. ncbi request reprint Raloxifene, an oestrogen-receptor-beta-targeted therapy, inhibits androgen-independent prostate cancer growth: results from preclinical studies and a pilot phase II clinical trial
    Ronald L Shazer
    Louis Warschaw Prostate Cancer Center, Cedars Sinai Medical Center, 8631 West Third Street, Los Angeles, CA 90048, USA
    BJU Int 97:691-7. 2006

Detail Information

Publications31

  1. ncbi request reprint Ductal adenocarcinoma of the prostate
    Ronald L Shazer
    Louis Warschaw Prostate Cancer Center, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Clin Adv Hematol Oncol 2:393-5; discussion 396. 2004
  2. ncbi request reprint Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy
    David B Agus
    Cedars Sinai Prostate Cancer Center, Los Angeles, CA 90048, USA
    J Clin Oncol 25:675-81. 2007
    ..The aim of this single-arm phase II clinical study was to assess the efficacy and safety of single-agent pertuzumab in castration-resistant prostate cancer (CRPC) patients who had experienced progression after prior chemotherapy...
  3. ncbi request reprint Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer
    David B Agus
    Cedars Sinai Prostate Cancer Center and Medical Center, Los Angeles, CA 90048, USA
    J Clin Oncol 23:2534-43. 2005
    ..A clinical study was conducted to investigate safety and pharmacokinetics of pertuzumab and to perform a preliminary assessment of HER dimerization inhibition as a treatment strategy...
  4. ncbi request reprint Update on HER-kinase-directed therapy in prostate cancer
    Mitchell E Gross
    Louis Warschaw Prostate Cancer Center, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Clin Adv Hematol Oncol 2:53-6, 64. 2004
    ..These include antibodies, tyrosine kinase inhibitors, and novel strategies which seek to decrease HER2 expression...
  5. pmc HER kinase axis receptor dimer partner switching occurs in response to EGFR tyrosine kinase inhibition despite failure to block cellular proliferation
    Anjali Jain
    Sumner M Redstone Prostate Cancer Research Program, Cedars Sinai Medical Center, Los Angeles, California, USA
    Cancer Res 70:1989-99. 2010
    ..Furthermore, EGFR kinase inhibition induces HER kinase receptors to engage in alternative dimerization that can ultimately influence therapeutic selection and responsiveness...
  6. doi request reprint Beta-2-microglobulin expression correlates with high-grade prostate cancer and specific defects in androgen signaling
    Sheldon R Mink
    Louis Warschaw Prostate Cancer Center, Sumner M Redstone Prostate Cancer Research Program, Cedars Sinai Medical Center, Los Angeles, California, USA
    Prostate 70:1201-10. 2010
    ..In this study, we explore an interaction between beta2M expression, prostate cancer tissue, and the androgen signaling axis...
  7. pmc Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes
    Shannon M Mumenthaler
    Sumner M Redstone Prostate Cancer Research Program, Cedars Sinai Medical Center, Los Angeles, CA, USA
    Mol Cancer Ther 8:2882-93. 2009
    ..These findings support the idea that inhibiting Pim kinases, in combination with a chemotherapeutic agent, could play an important role in prostate cancer treatment by targeting the clinical problem of chemoresistance...
  8. ncbi request reprint 2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth
    Noriyuki Takai
    Division of Hematology Oncology, Cedars Sinai Medical Center UCLA School of Medicine, Los Angeles, CA 90048, USA
    Cancer 104:2701-8. 2005
    ..HER2 is a ligand-less member of the HER family that functions as the preferred coreceptor for epidermal growth factor receptor (EGFR), HER3, and HER4...
  9. doi request reprint Quantitative proteomic profiling identifies protein correlates to EGFR kinase inhibition
    Kian Kani
    University of Southern California, Los Angeles, CA 90033, USA
    Mol Cancer Ther 11:1071-81. 2012
    ..In doing so, we also were able to identify which proteins might be useful as markers for monitoring response and which proteins might be useful as markers for a priori prediction of response...
  10. ncbi request reprint Raloxifene, an oestrogen-receptor-beta-targeted therapy, inhibits androgen-independent prostate cancer growth: results from preclinical studies and a pilot phase II clinical trial
    Ronald L Shazer
    Louis Warschaw Prostate Cancer Center, Cedars Sinai Medical Center, 8631 West Third Street, Los Angeles, CA 90048, USA
    BJU Int 97:691-7. 2006
    ....
  11. doi request reprint Anterior gradient 2 (AGR2): blood-based biomarker elevated in metastatic prostate cancer associated with the neuroendocrine phenotype
    Kian Kani
    University of Southern California, Los Angeles, California 90033, USA
    Prostate 73:306-15. 2013
    ..Anterior gradient 2 (AGR2) is associated with metastatic progression in prostate cancer cells as well as other normal and malignant tissues. We investigated AGR2 expression in patients with metastatic prostate cancer...
  12. ncbi request reprint CVS-3983, a selective matriptase inhibitor, suppresses the growth of androgen independent prostate tumor xenografts
    Anna V Galkin
    Cedars Sinai Louis Warschaw Prostate Cancer Center, Los Angeles, California 90045, USA
    Prostate 61:228-35. 2004
    ..We studied the effects of CVS-3983, a selective small molecule matriptase inhibitor, on the growth of the androgen independent (AI) CWR22R and CWRSA6 human prostate cancer xenograft models...
  13. ncbi request reprint Inhibition of HER-kinase activation prevents ERK-mediated degradation of PPARgamma
    Michael Hedvat
    Louis Warschaw Prostate Cancer Center, Cedars Sinai Medical Center, 8631 West Third Street, Suite 1001E, Los Angeles, CA 90048, USA
    Cancer Cell 5:565-74. 2004
    ..This study introduces a novel concept of an in vivo crosstalk between the HER-kinase axis and PPARgamma pathways, ultimately leading to negative regulation of PPARgamma activity and tumor growth inhibition...
  14. doi request reprint Body image predicts quality of life in men with prostate cancer
    Megan Taylor-Ford
    Department of Psychology, University of Southern California, Los Angeles, CA 90089 1061, USA
    Psychooncology 22:756-61. 2013
    ..The present study investigated how body image changes over time and the relations between changes in body image and quality of life (QOL) in men with prostate cancer...
  15. ncbi request reprint Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancer
    William D Fox
    Cedars Sinai Prostate Cancer Center, Los Angeles, California 90048, USA
    Clin Cancer Res 8:3226-31. 2002
    ..We administered 5 mg/kg rhu alpha VEGF i.p. twice weekly as a single agent and together with paclitaxel to established CWR22R xenografts...
  16. pmc A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer
    Mitchell Gross
    Louis Warschaw Prostate Cancer Center, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    BMC Cancer 7:142. 2007
    ..Erlotinib is a specific inhibitor of the tyrosine-kinase activity of EGFR. The goal of this study is to determine the anti-cancer activity docetaxel combined with erlotinib for the treatment of elderly subjects with AIPC...
  17. pmc Epithelial membrane protein-1 is a biomarker of gefitinib resistance
    Anjali Jain
    Louis Warschaw Prostate Cancer Center, Los Angeles, CA 90048, USA
    Proc Natl Acad Sci U S A 102:11858-63. 2005
    ..This report suggests the role of the adhesion molecule, EMP-1, as a biomarker of gefitinib clinical resistance, and further suggests a probable cross-talk between this molecule and the EGFR signaling pathway...
  18. ncbi request reprint Targeting the HER-kinase axis in cancer
    Mitchell E Gross
    Louis Warschaw Prostate Cancer Center, Cedars Sinai Medical Center, Los Angeles, CA, USA
    Semin Oncol 31:9-20. 2004
    ..This review focuses on the basic biology underlying HER-kinase pathway activation and the current state of development for agents that target this axis. In particular, the importance of pan-HER inhibitors is discussed...
  19. pmc Evolutionary modeling of combination treatment strategies to overcome resistance to tyrosine kinase inhibitors in non-small cell lung cancer
    Shannon M Mumenthaler
    Center for Applied Molecular Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA
    Mol Pharm 8:2069-79. 2011
    ....
  20. ncbi request reprint PPARgamma signaling: one size fits all?
    Anjali Jain
    Louis Warschaw Prostate Cancer Center, Cedars Sinai Prostate Cancer Center, Los Angeles, California 90048, USA
    Cell Cycle 3:1352-4. 2004
    ..Outcome of PPARgamma activation in cancer cells is not one-dimensional. PPARgamma signaling is dependent upon PPARgamma ligand affinity and binding characteristics, target cell context and interacting signaling networks...
  21. pmc A physical sciences network characterization of non-tumorigenic and metastatic cells
    David B Agus
    Center for Applied Molecular Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
    Sci Rep 3:1449. 2013
    ....
  22. ncbi request reprint Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth
    David B Agus
    Cedars Sinai Prostate Cancer Center, Los Angeles, California 90048, USA
    Cancer Cell 2:127-37. 2002
    ..We demonstrate that the in vitro and in vivo growth of several breast and prostate tumor models is inhibited by 2C4 treatment...
  23. pmc Cancer-associated fibroblasts derived from EGFR-TKI-resistant tumors reverse EGFR pathway inhibition by EGFR-TKIs
    Sheldon R Mink
    Cedars Sinai Medical Center, 8700 Beverly Boulevard, Davis 6012, Los Angeles, CA 90048, USA
    Mol Cancer Res 8:809-20. 2010
    ..This is the first demonstration that the tumor stroma is modified with acquisition of EGFR-TKI resistance and that it further contributes in promoting drug resistance...
  24. ncbi request reprint A perspective on protein profiling of blood
    Jonathan E Katz
    Louis Warschaw Prostate Cancer Center, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    BJU Int 96:477-82. 2005
  25. doi request reprint Precursor-ion mass re-estimation improves peptide identification on hybrid instruments
    Roland Luethy
    Spielberg Family Center for Applied Proteomics, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    J Proteome Res 7:4031-9. 2008
    ..These results demonstrate integration of msPrefix into traditional shotgun proteomics workflows significantly improves identification results...
  26. ncbi request reprint Clinical proteomics: the promises and challenges of mass spectrometry-based biomarker discovery
    Imelda E deVera
    Center for Applied Molecular Medicine at Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Clin Adv Hematol Oncol 4:541-9. 2006
    ..Particular emphasis is placed on those aspects strongly associated with reproducibility from both clinical and laboratory perspectives...
  27. doi request reprint Predictors of affect following treatment decision-making for prostate cancer: conversations, cognitive processing, and coping
    Kysa M Christie
    Department of Psychology, University of Southern California, Los Angeles, CA 90089, USA
    Psychooncology 18:508-14. 2009
    ..We further predicted that cognitive processing, coping, and patient understanding of treatment options would mediate this association...
  28. ncbi request reprint TMEFF2 is an androgen-regulated gene exhibiting antiproliferative effects in prostate cancer cells
    Sigal Gery
    Division of Hematology Oncology, Cedars Sinai Medical Center, Los Angeles, California, CA 90048, USA
    Oncogene 21:4739-46. 2002
    ....
  29. pmc The current state of preclinical prostate cancer animal models
    Kenneth J Pienta
    University of Michigan, Department of Internal Medicine, Ann Arbor, MI, USA
    Prostate 68:629-39. 2008
    ..It should be possible to apply the knowledge gained molecular and epigenetic studies to develop new cell lines and models that mimic progressive and fatal prostate cancer and ultimately improve interventions...
  30. ncbi request reprint Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse
    Susan M Henshall
    Cancer Research Program, Garvan Institute of Medical Research, St Vincent s Hospital, Darlinghurst, Sydney, New South Wales 2010, Australia
    Cancer Res 63:4196-203. 2003
    ....
  31. ncbi request reprint 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts
    David B Solit
    Program in Cell Biology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 8:986-93. 2002
    ....